76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Aldeyra Therapeutics Inc
Closed
3.87 10.57
Overview
Share price change
24h
Min
3.5
Max
3.92
Income | 5.9M -9.9M |
|---|---|
EPS | -0.17 |
Profit margin | -6,465.066 |
Employees | 8 |
EBITDA | 5.9M -9.4M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +165.81% upside |
Next Earnings | 30 Jul 2025 |
|---|
Market Cap | 53M 185M |
|---|---|
Previous open | -6.7 |
Previous close | 3.87 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Aldeyra Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Aldeyra Therapeutics Inc Forecast
Price Target
By TipRanks
165.81% upside
12 Months Forecast
Average 9.33 USD 165.81%
High 11 USD
Low 6 USD
Based on 6 Wall Street analysts offering 12 month price targets forAldeyra Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
